NPA101.3 is an orally active RET receptor tyrosine kinase and VEGFR2 inhibitor ( RET IC 50 = 0.001 μM, RET V804M IC 50 = 0.008 μM, VEGFR2 IC 50 = 0.003 μM). NPA101.3 inhibits purified TRKA ( IC 50 = 32 nM) and CSF1R ( IC 50 = 46 nM). NPA101.3 completely suppresses tumor formation in RET /C634Y -transformed cells and also attenuates tumor formation in HRAS /G12V -transformed cells. NPA101.3 can be used in the research of RET -driven cancers.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > RET | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > Trk Receptor | Products > Signaling Pathways > c-Fms
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.